Polimorfismos genéticos como predictores de toxicidad tardía inducida por radiación en pacientes con c´ancer de próstata
Abstract
Genetic polymorphisms are genetic variations found in individuals, that is, their phenotypic differences and / or susceptibilities to certain diseases are 0.1 % variation, while 99.9 % of the DNA sequence of two different individuals it’s the same. Most of the SNPs (single nucleotide genetic polymorphism) have two alleles which are represented by a substitution of one base for another, they are classified as main or ”wild.a llele and rare or mutant allele. Since humans are diploid, an individual can have one of three genotypes: homozygous for the most common allele, heterozygous, or homozygous for the least common allele.
The study of these variations has various applications in the fields of medicine and biotechnology. The objective is to reveal some of the main polymorphisms with greater statistical significance that have been studied and published in high impact articles in the last decade worldwide, related to genitourinary and rectal toxicity in patients with prostate cancer treated with radiation therapy.
Downloads
References
Sarah L Kerns, Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy, Cancer Discov, 2014 Feb;4(2):155-65.
Ruiz J. Relaci´on de la susceptibilidad gen´etica y de las caracter´ısticas anatomopatol´ogicas del c´ancer de pr´ostata con los polimorfismos de nucle´otido simple. Universidad Aut´onoma de Barcelona 2012.
Technologic issues in GWAS and follow-up studies. NCI 2007.
Kerns SL, Ostrer H, Rosenstein BS: Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. Cancer Discov 4:155-165, 2014.
Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76: S3–9.
Defraene G, Van den Bergh L, AlMamgani A, et al. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82:1233–42.
Cella L, D’Avino V, Liuzzi R, et al. Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiat Oncol. 2013; 8:22.
Edvardsen H, Landmark-Hoyvik H, Reinertsen KV, et al. SNP in TXNRD2 associated with radiation-induced fi- brosis: a study of genetic variation in reactive oxygen species metabolism and signaling. Int J Radiat Oncol Biol Phys. 2013; 86:791–9.
Andreassen CN, Barnett GC, Kerns SL, et al. Analysis of 5434 patients shows a link between the ATM codon 1853 SNP and the risk of radiationinduced toxicity. European Society for Radiotherapy and Oncology (ESTRO); Vienna, Austria. 2014.
Kerns SL, CMLW, Andreassen CN, et al. Radiogenomics: the search for genetic predictors of radiotherapy response. Future oncology. 2014; 10:2391–406.
Guy RT, Santago P, Langefeld CD. Bootstrap aggregating of alternating decision trees to detect sets of SNPs that associate with disease. Genet Epidemiol. 2012; 36:99–106.
Zhang Y. A novel bayesian graphical model for genome-wide multi-SNP association mapping. Genet Epidemiol. 2012; 36:36–47.
Barry S. Rosenstein, Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity. Semin Radiat Oncol 27:300-309, 2017.
Sarah L. Kerns, Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy, JNCI J Natl Cancer Inst (2020) 112(2): djz075
